C-LJJAAgeCurve
single-cell multiomics, AI, aging diagnostics
discoverydiscovering
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-LJJA
C-LJJAC-LJJAsingle-cell multiomics, AI, aging diagnostics
0-100 chain-logic scale · 15 dimensions · scored on public evidence
AgeCurve single-cell multiomics, AI, aging diagnostics
AgeCurve is building advanced aging diagnostics and therapeutics tools by combining somatic genotype with cellular phenotype at the single-cell level. The company applies machine learning and AI to develop an aging drug platform for precision drug optimisation at the individual level. Its site highlights a Geroscience study titled "Cell Tree Rings: the structure of somatic evolution as a human aging timer."
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
AgeCurve — Far from goals · Lower middle. Derived deterministically from 2 extracted project(s). Most-advanced status: undisclosed. Band: far. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic